MeiraGTx Holdings plc Asset Acquisition Consideration Transferred Contingent Consideration
MeiraGTx Holdings plc (MGTX) reported Asset Acquisition Consideration Transferred Contingent Consideration of $61.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration · last filed 2026-08-13
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for the quarter ending 2026-06-30 was -$859.00K, a 410.11% decline year-over-year.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for the quarter ending 2026-03-31 was $920.00K, a 49.59% increase year-over-year.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for the quarter ending 2025-12-31 was $527.00K.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for the quarter ending 2025-09-30 was -$139.00K, a 119.41% decline year-over-year.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for fiscal 2025 was $1.28M, a 50.41% increase from fiscal 2024.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for fiscal 2024 was $851.00K, a 67.36% decline from fiscal 2023.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for fiscal 2023 was $2.61M, a 63.31% decline from fiscal 2022.
- MeiraGTx Holdings plc asset acquisition consideration transferred contingent consideration for fiscal 2022 was $7.11M.
| Period end | Asset Acquisition Consideration Transferred Contingent Consideration 3 month | Asset Acquisition Consideration Transferred Contingent Consideration 6 month | Asset Acquisition Consideration Transferred Contingent Consideration 9 month | Asset Acquisition Consideration Transferred Contingent Consideration 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$859.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $61.00K 10-Q · filed 2026-08-13 | $588.00K derived: sum of 3 quarters · filed 2026-08-13 | $449.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $920.00K 10-Q · filed 2026-05-14 | $1.45M derived: sum of 2 quarters · filed 2026-05-14 | $1.31M derived: sum of 3 quarters · filed 2026-05-14 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $388.00K derived: sum of 2 quarters · filed 2026-03-30 | $665.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.28M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $138.00K derived: sum of 2 quarters · filed 2026-08-13 | $753.00K 10-Q · filed 2025-11-13 | -$293.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $892.00K 10-Q · filed 2026-08-13 | -$154.00K derived: sum of 3 quarters · filed 2026-08-13 | $562.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $615.00K 10-Q · filed 2026-05-14 | -$431.00K derived: sum of 2 quarters · filed 2026-05-14 | $285.00K derived: sum of 3 quarters · filed 2026-05-14 | -$92.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$330.00K derived: sum of 2 quarters · filed 2026-03-30 | -$707.00K derived: sum of 3 quarters · filed 2026-03-30 | $851.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $716.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $339.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.90M 10-Q · filed 2025-11-13 | $1.56M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.18M 10-Q · filed 2025-08-14 | $847.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.40M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.56M 10-Q · filed 2025-05-13 | $1.22M derived: sum of 2 quarters · filed 2025-05-13 | $1.78M derived: sum of 3 quarters · filed 2025-05-13 | $1.00M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $222.00K derived: sum of 2 quarters · filed 2025-03-13 | -$555.00K derived: sum of 3 quarters · filed 2025-03-13 | $2.61M 10-K · filed 2025-03-13 |
| 2023-09-30 | $556.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$221.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.94M 10-Q · filed 2024-11-13 | $2.45M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$777.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.38M 10-Q · filed 2024-08-12 | $1.89M derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | $3.16M 10-Q · filed 2024-05-09 | $2.67M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$492.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $7.11M 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $7.60M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |